Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0018681 (headache)
 56,091 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

In nine of 62 children with benign occipital epilepsy (BOE) the onset was stormy and alarming. The first and often only seizure was characterised by prolonged loss of consciousness lasting up to 12 hours, suggesting an acute cerebral insult. In all but one case there was a tonic aversion either of eyes alone or of both head and eyes which was interpreted as conjugate deviation. The other accompanying ictal motor phenomena were either partial or generalised convulsions. In five patients the seizure was heralded by a headache, and in five cases was accompanied by vomiting. The seizure began with visual symptoms in only one patient. The seizure occurred while awake in seven and during sleep in two. The age at onset was from 3 1/4 to 10 years. Interictal EEGs showed occipital discharges typical of BOE, and the clinical course was benign. In four cases a few partial or complex partial seizures recurred during subsequent anticonvulsant therapy, but in five cases seizures never recurred. Anticonvulsants were discontinued in five patients who remained free from seizures for one to 11 1/2 years after withdrawal of treatment. Sudden coma in a child associated with focal features such as tonic deviation of the head or eyes or both may represent a benign seizure disorder.
 ...
PMID:Stormy onset with prolonged loss of consciousness in benign childhood epilepsy with occipital paroxysms. 154 98

1. Vigabatrin (GVG) was given in a single-blind fashion to 89 patients with complex partial seizures (CPS) refractory to conventional drugs. 2. The median number of CPS per month decreased from 11.0 to 5.0 after addition of GVG, and 51% of patients had a 50% or greater decrease in CPS frequency (P less than 0.001). 3. Side effects (principally drowsiness, ataxia, headache) occurred mainly during the initiation of therapy and decreased during therapy. After 12 weeks on GVG side effects significantly interfered with functioning in only 13% of patients, and the efficacy: toxicity ratio warranted continued administration in 74% of patients. 4. Co-administration of GVG resulted in a mean decrease of 20% in phenytoin serum concentration (P less than 0.001). 5. Sixty-six patients having a favourable response to GVG during the single-blind study have been followed for 6-54 (median 33) months on GVG. Only 17 patients have dropped out of long-term follow-up due to break through seizures and/or side effects. No serious systemic or neurological toxicity has been detected.
 ...
PMID:A multicentre study of vigabatrin for drug-resistant epilepsy. 266 6

Intracarotid injection of 133-Xenon and recording of wash out of radioactivity by 254 external stationary detectors was used to measure rCBF. Initial slope values were calculated by a computer, translated into color code and displayed on a TV-screen. rCBF in patients with epilepsy has been the object of former studies. Those who had a cortical focus showed corresponding high blood flow values during attack and during EEG paroxysms without clinical attacks. On the contrary, all other patients with a cortical focus were normal. Patients with complex partial seizures displayed no abnormalities interictally. During generalized epileptic seizures rCBF and metabolism doubled. Distinction must be made between patients with aura (classic migraine) and patients without aura (common migraine). In the latter CBF was normal or slightly elevated. In the former the aura symptoms are associated with reduced CBF. The reduction usually starts posteriorly and spreads gradually anteriorly. rCBF remains depressed for up to several hours into the headache phase. After 8-12 hours a reactive hyperemia may ensue. In common migraine rCBF remains normal throughout the attack. During classic migraine attacks rCBF is depressed whereas it is increased during epileptic attacks. Thus rCBF studies further strengthen the differences between epilepsy and migraine.
 ...
PMID:Regional cerebral blood flow (rCBF) studies in migraine and epilepsy. 360 67

The irreversible GABA transaminase inhibitor vigabatrin (VGB) was given in a single-blind fashion to 89 patients with complex partial seizures (CPS) refractory to conventional drugs. The median number of CPS per month decreased from 11.0 to 5.0 after addition of VGB, and 51% of patients had a 50% or greater decrease in CPS frequency (p less than 0.001). Side effects (principally drowsiness, ataxia, and headache) occurred mainly during the initiation of therapy and decreased during therapy. After 12 weeks on VGB, side effects significantly interfered with functioning in only 13% of patients, and the efficacy:toxicity ratio warranted continued administration in 74% of patients. Coadministration of VGB resulted in a mean decrease of 20% in phenytoin serum concentration (p less than 0.001). Sixty-six patients with a favorable response to VGB during the single-blind study have been followed for a median of 16.7 months on VGB. No serious systemic or neurologic toxicity has been detected, and most patients have retained their initial favorable CPS control.
 ...
PMID:Vigabatrin for refractory complex partial seizures: multicenter single-blind study with long-term follow-up. 380 98

Methsuximide (MSM; Celontin) was administered for 8 weeks to 26 patients with complex partial seizures (CPS) refractory to phenytoin and carbamazepine and phenobarbital or primidone. A 50% or greater reduction in CPS frequency was obtained in eight patients. MSM therapy was continued chronically in these eight patients, and five continued to have a 50% or greater reduction in CPS frequency after 3 to 34 months of follow-up. Drowsiness, gastrointestinal disturbance, hiccups, irritability, and headache were the common side effects of MSM. No serious toxicity occurred. N-desmethylmethsuximide was the principal substance detected in plasma and had the following pharmacokinetic values: accumulation half-life, 49.7 hours; time to steady state, 10.4 days; elimination half-life, 72.2 hours; therapeutic range of plasma concentration, 10 to 30 mg per liter. Plasma concentrations of phenytoin and phenobarbital derived from primidone rose significantly (p less than 0.05) after addition of MSM.
 ...
PMID:Methsuximide for complex partial seizures: efficacy, toxicity, clinical pharmacology, and drug interactions. 640 91

Clinical and electroencephalographical investigations were made on the 234 patients with neuropsychiatric disorders, showing small sharp spikes (sss) on EEG. Incidence of sss was significantly higher in patients with epilepsy (8.6%) than in the non-epileptic cases (2.5%), especially in early age groups (11-35 years). Some differences in clinical features and in characteristics of sss were found between the epileptic patients and the non-epileptic patients; namely, 1) In majority of the subjects (97%), sss were observed exclusively in stage 1 and 2 of sleep, however, 8 epileptic patients exhibited sss in deep sleep (stage 3) or in awake state, as well as in light sleep. 2) In the non-epileptic group, females (3.4%) showed significantly higher incidence of sss than males (1.7%), while there was no sex difference in the epileptic group. 3) Of the non-epileptic patients, 45% had autonomic symptoms, such as headache, dizziness, tinnitus, nausea and vomiting, while there was no significant correlation between particular neuropsychiatric diagnosis and the EEG pattern. Among the non-epileptics, 72% showed normal EEG except for sss and in 89% sss appeared bilaterally but commonly bilaterally independently. 4) As to relation of sss to seizure types of epilepsy, complex partial seizures showed significantly higher incidence of sss (25.2%) than simple partial seizures (7.5%) and generalized tonic-clonic seizures (6.5%). In the patients with epilepsy, sss were often observed unilaterally predominantly (49%), especially in the patients with complex partial seizure (57%). In complex partial seizure, unilateral sss coincided with laterality of anterior-temporal seizure discharges in 68%. According to the results, the authors suggested that sss has some electroencephalographical significance, probably on mechanisms relating to epileptogenic dysfunction, particularly that of complex partial seizures.
 ...
PMID:[Clinico-electroencephalographical significance of small sharp spikes]. 686 May

A retrospective method was used to estimate the incidence of recurring motion-sickness, cyclic vomiting and abdominal pain considered as different manifestations of a so-called periodic syndrome in 100 migraine sufferers, 100 epileptics and 100 control subjects in the pediatric age group. Such recurrent symptoms are significantly more frequent in those suffering from migraine than in the other two groups. Examination of subgroups of patients affected by particular forms of migraine (classical and common) and of epilepsy (generalized seizures, simple partial seizures, complex partial seizures) contributed little new to our understanding of the nature of periodic syndrome. It is concluded that the above symptoms of periodic syndrome should generally be considered as manifestations of a migrainous rather than of an epileptic disorder.
Cephalalgia 1983 Jun
PMID:Cyclic vomiting and recurrent abdominal pains as migraine or epileptic equivalents. 687 85

Neoplastic meningitis, an unusual complication of systemic cancer, is becoming more common as cancer patients live longer. Although leptomeningeal metastases from solid tumors are usually associated with multifocal neurological signs, the authors report on 4 patients who presented with normal findings on neurological examination. One man had severe headache and complex partial seizures. Magnetic resonance imaging (MRI) of the brain revealed gadolinium enhancement of multiple cranial nerves. Cerebrospinal fluid (CSF) cytology was positive for melanoma. One woman presented with severe migratory retroorbital headaches. MRIs of the brain with and without gadolinium appeared normal. CSF cytology was positive for pulmonary adenocarcinoma. One man presented with morning headache, and a woman presented with back pain. Both had CSF cytologies positive for lymphoma. Neoplastic meningitis can occur without abnormalities on neurological or MRI examinations. Lumbar punctures should be performed on cancer patients with severe, unusual, or prolonged headaches.
 ...
PMID:Neoplastic meningitis with normal neurological findings. Magnetic resonance imaging results. 757 52

Tiagabine is a new antiepileptic drug which acts by a novel mechanism, inhibiting the reuptake of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA) into neurons and glia. A double-blind, placebo-controlled, crossover trial was undertaken, based upon a response-dependent design. Ninety-four patients with complex partial seizures with or without secondary generalised tonic-clonic seizures were recruited into an open screening phase and tiagabine was added to their existing drug therapy in doses titrated to reduce seizure frequency by > or = 25% or to the limit of tolerance. Forty-six responders were subsequently randomised to a double-blind crossover trial in which tiagabine was compared with placebo. Forty-two patients completed the trial. A significant reduction in the frequency of complex partial and secondary generalised tonic clonic seizures was seen. Twenty-six percent had a reduction of > or = 50% in the frequency of their complex partial seizures, and of the 27 patients who also had secondary generalised tonic clonic seizures, 63% experienced a reduction of > or = 50%. No interactions with baseline antiepileptic drugs were detected and no serious adverse reactions occurred. The commonest adverse events were tiredness, dizziness and headache. We conclude that tiagabine has promising antiepileptic effects. Further trials are underway.
 ...
PMID:Adjunctive treatment of partial seizures with tiagabine: a placebo-controlled trial. 764 74

The neuropsychological effects of the GABA-reuptake blocker, tiagabine-HCl, were tested in an open trial of 22 adult patients with refractory partial epilepsy followed by a double-blind, placebo-controlled, cross-over trial in 12 subjects. Nineteen patients completed the initial open titration and fixed-dose phase of the study and 11 patients completed the double-blind phase. The median daily tiagabine dose was 32 mg during the open fixed dose and 24 mg during the double-blind periods. Neuropsychological evaluation did not show any significant effect on cognitive function in the open or double-blind phases. In this group of patients no statistically significant difference in the frequency of the total number of seizures or complex partial seizures was found in the open or double-blind stages. Seizure severity was significantly less in the open fixed dose than in the baseline period, but was not significantly different between the two double-blind periods. Reported side effects were transient, most commonly aggression/irritability, lethargy, headache and drowsiness. No significant EEG changes were observed.
 ...
PMID:Neuropsychological effects of tiagabine, a potential new antiepileptic drug. 804 51


1 2 3 4 Next >>